131 related articles for article (PubMed ID: 10719867)
21. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model.
Marecos E; Weissleder R; Bogdanov A
Bioconjug Chem; 1998; 9(2):184-91. PubMed ID: 9548533
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
[TBL] [Abstract][Full Text] [Related]
23. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts.
Remsen LG; Pagel MA; McCormick CI; Fiamengo SA; Sexton G; Neuwelt EA
Anesth Analg; 1999 Mar; 88(3):559-67. PubMed ID: 10072006
[TBL] [Abstract][Full Text] [Related]
24. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
25. Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Muldoon LL; Pagel MA; Netto JP; Neuwelt EA
J Neurooncol; 2016 Feb; 126(3):447-54. PubMed ID: 26694547
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
27. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma.
Yeh MY; Roffler SR; Yu MH
Int J Cancer; 1992 May; 51(2):274-82. PubMed ID: 1568795
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.
Sivam GP; Martin PJ; Reisfeld RA; Mueller BM
Cancer Res; 1995 Jun; 55(11):2352-6. PubMed ID: 7757986
[TBL] [Abstract][Full Text] [Related]
30. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone decreases the delivery of tumor-specific monoclonal antibody to both intracerebral and subcutaneous tumor xenografts.
Neuwelt EA; Barnett PA; Ramsey FL; Hellström I; Hellström KE; McCormick CI
Neurosurgery; 1993 Sep; 33(3):478-84; discussion 484. PubMed ID: 8413880
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
Siegal T; Horowitz A; Gabizon A
J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617
[TBL] [Abstract][Full Text] [Related]
34. Human monoclonal antibody-drug conjugates in the experimental treatment of malignant gliomas--studies in vitro and in vivo.
Zhu J; Takahashi H; Nakazawa S
Neurol Med Chir (Tokyo); 1994 May; 34(5):279-85. PubMed ID: 7519748
[TBL] [Abstract][Full Text] [Related]
35. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis.
Remsen LG; McCormick CI; Roman-Goldstein S; Nilaver G; Weissleder R; Bogdanov A; Hellström I; Kroll RA; Neuwelt EA
AJNR Am J Neuroradiol; 1996 Mar; 17(3):411-8. PubMed ID: 8881233
[TBL] [Abstract][Full Text] [Related]
36. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts.
Neuwelt EA; Barnett PA; Hellström KE; Hellström I; McCormick CI; Ramsey FL
J Nucl Med; 1994 Nov; 35(11):1831-41. PubMed ID: 7965166
[TBL] [Abstract][Full Text] [Related]
37. Determination of immunoreactivity of doxorubicin antibody immunoconjugates by a Le(y) competitive RIA.
Zhao H; Willner D; Cleaveland JS; Braslawsky GR; Brown JP
Bioconjug Chem; 1992; 3(6):549-53. PubMed ID: 1361153
[TBL] [Abstract][Full Text] [Related]
38. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
[TBL] [Abstract][Full Text] [Related]
39. Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model.
Burkhardt JK; Santillan A; Hofstetter CP; Christos P; Berry N; Shin BJ; Foley CP; Gürsel DB; Ballon DJ; Gobin YP; Boockvar JA
J Exp Ther Oncol; 2012; 10(1):31-7. PubMed ID: 22946342
[TBL] [Abstract][Full Text] [Related]
40. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
